Saenz, D. T., Fiskus, W., Manshouri, T., Rajapakshe, K., Krieger, S., Sun, B., . . . Bhalla, K. N. (2016). BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia.
Chicago-стиль цитированияSaenz, Dyana T., et al. "BET Protein Bromodomain Inhibitor-based Combinations Are Highly Active against Post-myeloproliferative Neoplasm Secondary AML Cells." Leukemia 2016.
MLA-цитированиеSaenz, Dyana T., et al. "BET Protein Bromodomain Inhibitor-based Combinations Are Highly Active against Post-myeloproliferative Neoplasm Secondary AML Cells." Leukemia 2016.
Предупреждение: эти цитированмия не могут быть всегда правильны на 100%.